Hypermobile Online Pain managemEnt (HOPE) for people with hypermobile Ehlers-Danlos Syndrome (hEDS) or Hypermobility Spectrum Disorder (HSD): a pilot randomised controlled trial of feasibility, acceptability and effectiveness

Not Applicable

Active, not recruiting

• Conditions: hypermobile Ehlers-Danlos Syndrome (hEDS); Hypermobility Spectrum Disorder (HSD); Joint Hypermobility Syndrome; Ehlers-Danlos Syndrome - Hypermobile Type; Musculoskeletal - Other muscular and skeletal disorders

• Registration Number: ACTRN12623001323617
• Lead Sponsor: Macquarie University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-12-18
• Last Update Posted: 10 June 2024

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 73

Inclusion Criteria

•Adults aged 18 and over
•Australian residents
•Diagnosed with hEDS or HSD or Joint Hypermobility Syndrome (JHS) or Ehlers-Danlos Syndrome – Hypermobility Type (EDS-HT) by a medical doctor (e.g. rheumatologist, geneticist, general practitioner)
•Presence of pain for more than 3 months
•Sufficient English proficiency to engage with program and interview
•Have access to a desktop/laptop and internet over the course of the program
•Stable dosage and type of pain medication in the last 3 months
•Stable medical or allied health interventions for pain (such as Physiotherapy, Psychology) in the last 3 months

Exclusion Criteria

•Severe depression (Patient Health Questionnaire (PHQ-9) score >=20)
•Significant suicidal ideation (PHQ-9 score >2 on item 9)
•Co-existing medical conditions causing pain not known to be associated with hEDS/HSD such as active cancer, active inflammatory joint conditions

Study & Design

• Study Type: Interventional
• Study Design: Not specified